RxCelerate and Constructive Bio announce partnership to advance next-generation therapeutics
Cambridge, UK – 19 November 2025 – Constructive Bio and RxCelerate have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases.
The collaboration brings together RxCelerate’s integrated drug discovery and development expertise with Constructive Bio’s proprietary programmable biology platform. Built on the pillars of synthetic genomics and engineered translation, Constructive Bio’s platform enables the biological incorporation of non-canonical amino acids (ncAAs) into peptide, protein and biologic therapies.
By expanding the chemical diversity of proteins, Constructive Bio’s technology opens new avenues for designing biologics with enhanced properties and therapeutic potential. Under the agreement, RxCelerate will design and deliver comprehensive drug discovery programmes, leveraging Constructive Bio’s proprietary platform, to demonstrate how programmable biology can transform biologic drug development.
By combining their expertise, RxCelerate and Constructive Bio are advancing a new generation of biologics designed to address complex diseases with limited treatment options.
Dr Jill Reckless, CEO at RxCelerate, said:
This partnership exemplifies how combining complementary strengths can accelerate innovation. Together, we aim to unlock new possibilities for next-generation therapeutics, demonstrating the full potential of Constructive Bio’s platform to create differentiated biologics that deliver meaningful benefits for patients.
Dr Ola Wlodek, CEO at Constructive Bio, said:
This collaboration demonstrates how rewriting life’s code can redefine what is possible in drug discovery - enabling entirely new classes of biologics for the world’s most challenging diseases with powerful new-to-nature chemistries. RxCelerate’s deep expertise and agile development model make them an ideal partner for us.
Dr Jon Heal, Executive Vice President of ProsaRx at RxCelerate, said:
This collaboration brings together RxCelerate’s full suite of in-house capabilities, from in silico design and bioengineering to complex biology, powered by our proprietary ProsaRx platforms. Constructive Bio’s groundbreaking programmable biology technology opens new design space for biologics, and together we’re building a programme that could deliver truly novel therapeutics for diseases where current treatments fall short.
